Fact based stock research
Sanofi (ENXTPA:SAN)


Sanofi stock research in summary

sanofi.com


Sanofi shares have a SELL rating. While they are good value, they are riskily financed, and show below average growth. We recommend selling Sanofi shares.


Latest Obermatt Ranks


Country France
Industry Pharmaceuticals
Index EURO STOXX 50, SBF 120, CAC 40, CAC All
Size class XX-Large

May 10, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()




Research History: Sanofi

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
77
81
92
85
STOCK GROWTH RANKS
52
56
21
2
STOCK SAFETY RANKS
56
48
46
36
COMBINED STOCK RANKS
75
83
88
27

Last update of Combined Rank: 10-May-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Sanofi in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 10-May-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Sanofi; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
59
35
37
9
PROFIT GROWTH
62
30
30
20
STOCK RETURNS
38
66
29
14
CONSOLIDATED RANK: GROWTH
52
56
21
2

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Sanofi.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
40
38
40
49
REFINANCING
61
58
40
43
LIQUIDITY
46
47
54
46
CONSOLIDATED RANK: SAFETY
56
48
46
36

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Sanofi and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Sanofi from May 10, 2018.